These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 38741610)
1. Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors. Goldin M; Smith K; Koulas I; Leung T; Ravi M; Parhar S; Shah S; Floyd K; Ohanesian L; Bain R; Defonte D; Ochani K; Lin A; Patel B; Tsaftaridis N; Jnani J; Spyropoulos AC TH Open; 2024 Apr; 8(2):e209-e215. PubMed ID: 38741610 [No Abstract] [Full Text] [Related]
2. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ; Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876 [TBL] [Abstract][Full Text] [Related]
3. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series. Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa. Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161 [TBL] [Abstract][Full Text] [Related]
5. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage. Troyer C; Nguyen W; Xie A; Wimer D J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324 [TBL] [Abstract][Full Text] [Related]
6. Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center. Stevens VM; Trujillo T; Mueller SW; MacLaren R; Reynolds PM; Kiser TH Clin Appl Thromb Hemost; 2019; 25():1076029619896619. PubMed ID: 31876159 [TBL] [Abstract][Full Text] [Related]
7. Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ; Thromb Haemost; 2022 Jun; 122(6):998-1005. PubMed ID: 34996121 [TBL] [Abstract][Full Text] [Related]
8. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578 [TBL] [Abstract][Full Text] [Related]
9. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. Dobesh PP; Fermann GJ; Christoph MJ; Koch B; Lesén E; Chen H; Lovelace B; Dettling T; Danese M; Ulloa J; Danese S; Coleman CI Res Pract Thromb Haemost; 2023 Aug; 7(6):102192. PubMed ID: 37753225 [TBL] [Abstract][Full Text] [Related]
10. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays. Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587 [TBL] [Abstract][Full Text] [Related]
11. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827 [TBL] [Abstract][Full Text] [Related]
12. Real-world utilization of andexanet alfa. Brown CS; Scott RA; Sridharan M; Rabinstein AA Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672 [TBL] [Abstract][Full Text] [Related]
13. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series. Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008 [TBL] [Abstract][Full Text] [Related]
15. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis. Shrestha DB; Budhathoki P; Adhikari A; Shrestha S; Khati N; Mir WAY; Joshi T; Shrestha A Cureus; 2021 Dec; 13(12):e20632. PubMed ID: 35103198 [TBL] [Abstract][Full Text] [Related]
18. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920 [TBL] [Abstract][Full Text] [Related]